The funding announcement came with an unusual date: May 13, 2026. Shanghai Immunocan Biotech disclosed the round well in advance, a rarity in venture announcements. The substance is clear enough—the company says it has closed a RMB 250 million Series A, roughly $34.5 million to $36.8 million depending on exchange rates, to expand its suite of transgenic animals engineered to churn out fully human antibodies.
Vivo Capital led the round. Gold Mine Multi Family Office joined in, alongside existing investors Kingray Capital and TigerYeah Capital, both of which doubled down.
What Immunocan sells is decidedly not a drug. It's the infrastructure underneath: genetically altered mice, rabbits, and other creatures that pharmaceutical companies lease or license to hunt for novel antibody therapeutics. Think of it as picks-and-shovels for the biologics gold rush, except the shovels have been gene-edited at megabase scale.
Megabases and Mouse Models
The core technology is called MASIRT—Massive-fragment Across Species In situ Replacement Technology, a name that manages to be both precise and unwieldy. In practical terms, the platform swaps out massive stretches of an animal's genome, humanizing the immunoglobulin variable regions so the host can generate antibodies that look human enough to avoid immune rejection in patients.
Immunocan, which was founded in 2020, rolled out its first commercial mouse model, ImmuMab, in December 2022. Since then it has spun out a menagerie of specialized strains: heavy-chain-only mice for nanobody work, common light chain mice tailored for bispecific antibody development, a lambda-biased variant carrying 3.2 megabases of human immunoglobulin variable regions. There's even ImmuAlpaca, a mouse carrying alpaca-derived VHH sequences—because sometimes you need camelid biology in a rodent chassis.
The company is also working on rabbit platforms, which the fresh capital is meant to push toward commercial launch. Rabbits, for reasons of immune repertoire diversity, have their partisans in the antibody discovery world.
AI Gets Involved
Immunocan pairs its living tools with MabAI, an artificial intelligence engine that the company says is trained on more than 100 million "high-quality immune sequences" generated annually from its multi-species systems. The pitch: better hit rates, earlier flags on developability problems, faster timelines. Whether that holds up in head-to-head comparisons with competitors remains to be seen, but pharma buyers are paying attention.
The company has inked collaborations with what it describes as "multiple pharmaceutical companies," including several it claims are in the global top 10 by revenue. Names remain under wraps. In December 2024, Immunocan was accepted into Bayer Co.Lab's China site, gaining access to the German pharma giant's innovation infrastructure—a stamp of credibility, if not a commercial deal in itself.
A Crowded Landscape
Immunocan is hardly alone in this corner of biotech. OmniAb, Harbour BioMed, Alloy Therapeutics, Trianni—all offer transgenic mouse platforms with their own proprietary twists. The competitive moat comes down to repertoire diversity, speed to candidate, and how well the resulting antibodies survive the brutal winnowing process of preclinical and clinical development.
Immunocan is betting its cross-species approach and AI integration will matter enough to stand out. The company says it holds a global patent portfolio covering MASIRT technology in China, the EU, the U.S., and Japan. Patent estates in platform biotech can be formidable—or full of holes, depending on who's examining the claims.
The Money and What Comes Next
Vivo Capital, which led the Series A, is a 28-year-old healthcare-focused firm with $7.5 billion under management across 16 funds, according to Immunocan's announcement materials. Vivo has been active in cross-border biotech investments, particularly in platforms that serve multiple therapeutic programs rather than betting on a single molecule.
Immunocan previously raised RMB 50 million in a Pre-A round in August 2021, led by Kingray Capital. Lighthouse Capital advised on the current deal.
The Series A capital will fund the usual growth levers: expand the animal pipeline, commercialize the rabbit models, beef up the MabAI computational stack, hire more people. The company also plans to develop scaffold antibodies—off-the-shelf formats that can be customized for specific targets.
Immunocan operates from a facility on Xinlai Road in Shanghai's Jiading District. What it's selling, ultimately, is a faster route from biological insight to therapeutic candidate. Whether that proves lucrative depends on how many pharma companies decide the speed and diversity are worth the licensing fees—and whether Immunocan's engineered animals and algorithms actually deliver on the hit-rate promises. The next phase, as always, is proving it at scale.
